Thus, new therapeutic strategies are needed both for younger as well as for elderly and unfit patients who can only receive AML-stabilizing treatment; combination therapy including PI3K-Akt-mTOR inhibitors may then be an alternative therapeutic strategy [3,16,18]. Here, MTOR is linked to acute myeloid leukemia.